Displaying drugs 11751 - 11775 of 12282 in total
S-oxy-L-cysteine
Experimental
Zeatin
An aminopurine factor in plant extracts that induces cell division. (Grant & Hackh's Chemical Dict, 5th ed)
Experimental
Pinus densiflora whole
Experimental
Glyceryl laurate
Experimental
Matched Categories: … Compounds used in a research, industrial, or household setting …
Tilavonemab
Investigational
Trimethyltetradecylammonium
Investigational
Matched Categories: … Compounds used in a research, industrial, or household setting …
KP-1461
KP-1461 is a potent, non-chain-terminating, mutagenic deoxyribonucleoside analogue. Designated a DNA covert nucleoside, the drug consists of a modified base that incorporates randomly into HIV and pairs with multiple bases.
Investigational
Matched Description: … Designated a DNA covert nucleoside, the drug consists of a modified base that incorporates randomly into ... KP-1461 is a potent, non-chain-terminating, mutagenic deoxyribonucleoside analogue. …
beta-Naphthoflavone
β-Naphthoflavone, also known as 5,6-benzoflavone, is a potent agonist of the aryl hydrocarbon receptor and induces cytochromes P450 (CYPs) and uridine 5'-diphospho-glucuronosyltransferases (UGTs). It may be a chemopreventive agent.
Experimental
Matched Description: … β-Naphthoflavone, also known as 5,6-benzoflavone, is a potent agonist of the aryl hydrocarbon receptor ... It may be a chemopreventive agent. …
PF-04995274
Pf 04995274 is under investigation in clinical trial NCT01193062 (Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274).
Investigational
Matched Description: … Single Oral Dose Of PF-04995274). ... Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A …
SC-236
SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) that has been studied in cancer therapy , lower back pain , and inflammation , , , .
Experimental
Investigational
Matched Description: … SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) [L2964] that has been …
TOP-1288
TOP-1288 is under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis).
Investigational
Matched Description: … investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of …
Inarigivir soproxil
Inarigivir soproxil is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)).
Investigational
Matched Description: … soproxil is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of …
Rilematovir
Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)).
Investigational
Matched Description: … Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and ... Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With …
Miricorilant
Miricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)).
Investigational
Matched Description: … investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of …
UB-612
The UB-612 COVID-19 vaccine was developed by United Biomedical Inc Asia in Taipei as the first COVID-19 “multi-tope” protein-peptide vaccine made up of eight rationally designed components . The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell...
Investigational
Matched Description: … The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of ... a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the ... United Biomedical Inc Asia in Taipei as the first COVID-19 “multi-tope” protein-peptide vaccine made up of …
XL999
XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3. XL999 also inhibits FLT4 and...
Investigational
Matched Description: … XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth ... and indirectly through inhibition of the host angiogenic response. ... XL999 induces a cell-cycle block by a mechanism distinct from those previously identified and exhibits …
NUC B1000
NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to...
Investigational
Matched Description: … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct ... On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its ... [F3910] eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is …
YSIL6
YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.
Investigational
Matched Description: … YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid …
Ranirestat
Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels. It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy.
Investigational
Matched Iupac: … (3R)-2'-[(4-bromo-2-fluorophenyl)methyl]-2',3'-dihydro-1'H-spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine …
Matched Description: … It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy ... Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21 ... ) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels …
Matched Description: … It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy ... Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21 ... ) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels …
PRO-542
PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates.
Investigational
Matched Description: … PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from ... PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes …
CCR5 mAb
CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (HIV-1). It was generated by HGS using the Abgenix XenoMouse technology.
Investigational
Matched Description: … CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (HIV-1). ... CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor …
Efinopegdutide
Efinopegdutide is under investigation in clinical trial NCT03606057 (A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)).
Investigational
Matched Description: … of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults ... : a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)). ... Efinopegdutide is under investigation in clinical trial NCT03606057 (A Study to Investigate the Effect …
D2C7 immunotoxin
D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the Pseudomonas exotoxin, PE38-KDEL. D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas).
Investigational
Matched Description: … genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL. ... D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a …
Tezosentan
Tezosentan is an intravenous endothelin receptor A/B antagonist. Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.
Investigational
Matched Description: … Tezosentan is an intravenous endothelin receptor A/B antagonist. ... in patients with acute heart failure but studies have shown that it does not assist in the treatment of …
Dacetuzumab
Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells.
Investigational
Matched Description: … Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, ... It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells. …
Displaying drugs 11751 - 11775 of 12282 in total